补体结合性抗HLA抗体可独立预测肾移植受者抗体介导排斥治疗反应
该前瞻性队列纳入139例接受标准治疗的抗体介导排斥(ABMR)肾移植受者,于诊断时和治疗后3个月评估抗HLA供者特异性抗体(DSA)及其C1q结合能力。校正临床和组织学参数后,治疗后C1q结合性抗HLA DSA是全因移植物丢失的独立显著决定因素(校正风险比2.57,95%CI 1.29-5.12)。
要点
- 治疗后C1q结合性抗HLA DSA阳性者移植物丢失风险显著升高(校正HR 2.57)。
- 治疗后C1q结合性DSA阴性者肾功能显著改善且组织学活动性病变显著减轻。
- 基于GFR、cg病变和C1q结合性DSA的决策树模型可区分5个预后组。
核心结论
- 循环补体结合性抗HLA DSA是ABMR标准治疗后移植物结局的强独立预测因素。
研究设计与样本
- 前瞻性队列纳入139例接受标准治疗的ABMR肾移植受者。
- 标准治疗包括血浆置换、静脉注射免疫球蛋白和利妥昔单抗。
- 于诊断时和治疗后3个月系统评估临床、组织学及抗HLA DSA(含C1q结合能力)。
主要发现
- 治疗后C1q结合性抗HLA DSA阳性38例,阴性101例。
- 校正临床和组织学参数后,治疗后C1q结合性DSA与移植物丢失独立相关(校正HR 2.57,95%CI 1.29-5.12)。
- 101例治疗后C1q结合性DSA阴性者GFR显著改善,且肾小球炎、管周毛细血管炎、间质炎症、肾小管炎、C4d沉积和动脉内膜炎显著减少。
- 条件推断树模型基于GFR、cg病变和C1q结合性DSA识别出5个预后组(交叉验证准确率0.77)。
临床怎么用
- ABMR治疗后3个月检测C1q结合性抗HLA DSA有助于风险分层。
- 结合GFR、cg病变和C1q结合性DSA可辅助判断移植物预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A major hurdle to improving clinical care in the field of kidney transplantation is the lack of biomarkers of the response to antibody-mediated rejection (ABMR) treatment. To discover these we investigated the value of complement-binding donor-specific anti-HLA antibodies (DSAs) for evaluating the response to treatment. The study encompassed a prospective cohort of 139 kidney recipients with ABMR receiving the standard of care treatment, including plasma exchange, intravenous immunoglobulin and rituximab. Patients were systematically assessed at the time of diagnosis and three months after treatment initiation for clinical and allograft histological characteristics and anti-HLA DSAs, including their C1q-binding ability. After adjusting for clinical and histological parameters, post-treatment C1q-binding anti-HLA DSA was an independent and significant determinant of allograft loss (adjusted hazard ratio 2.57 (95% confidence interval 1.29-5.12). In 101 patients without post-treatment C1q-binding anti-HLA DSA there was a significantly improved glomerular filtration rate with significantly reduced glomerulitis, peritubular capillaritis, interstitial inflammation, tubulitis, C4d deposition, and endarteritis compared with 38 patients with posttreatment C1q-binding anti-HLA DSA. A conditional inference tree model identified five prognostic groups at the time of post-treatment evaluation based on glomerular filtration rate, presence of cg lesion and C1q-binding anti-HLA DSA (cross-validated accuracy: 0.77). Thus, circulating complement-binding anti-HLA DSAs are strong and independent predictors of allograft outcome after standard of care treatment in kidney recipients with ABMR.
引用
- Viglietti D, Bouatou Y, Kheav VD, et al. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney Int. 2018. PMID: 29801667. doi:10.1016/j.kint.2018.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。